Document is current

Article History

Accepted: 25 February 2025

First Online: 13 March 2025

Declarations

:

: No funding was received for the conduct of this study or the preparation of this article.

: Within 36 months, Shigeki Yamada has received honoraria from EA Pharma Co., Ltd. and Takeda Pharmaceutical Co., Ltd. Tomohiro Mizuno has received honoraria from Kyowa Kirin Co., Ltd. and Sumitomo Pharma Co., Ltd. Tomohiro Mizuno is an editorial board member of Clinical Drug Investigation. Tomohiro Mizuno was not involved in the selection of peer reviewers for the manuscript or in any of the subsequent editorial decisions. Masanori Nakanishi, Shinya Sakai, Daiki Hira, Takenao Koseki, Takeshi Matsubara, Hideki Yokoi, Motoko Yanagita, Tomohiro Terada, and Naotake Tsuboi have no conflicts of interest that are directly relevant to the content of this article.

: This research was approved by the ethics boards of Fujita Health University Hospital (ethics committee approval number: HM22-224) and Kyoto University Hospital (ethics committee approval number: R3634) and was conducted in accordance with the appropriate guidelines.

: Because this was a retrospective cohort study, an opt-out approach for obtaining informed consent was used with the approval of the ethics board.

: Not applicable.

: Data archiving is not mandated but data will be made available on reasonable request.

: Not applicable.

: MN and TM contributed to the study conception and design, analyzed the data, and drafted the manuscript. MN, SS, and HD interpreted the data. SS and HD contributed to drafting the manuscript and the study design. TK, YM, HY, MY, TT, SY, and NT designed the study and reviewed the manuscript. All authors read and approved the final version.